微轴流泵被证明可以挽救泵故障的心脏病患者的生命

对于 ST 段抬高型心肌梗死 (STEMI) 和心源性休克患者，与单独使用标准护理相比，使用微轴流泵 (Impella CP) 和标准护理可降低死亡风险。

Microaxial Flow Pump Reduces Mortality in STEMI Patients with Cardiogenic Shock

微轴流泵降低心源性休克 STEMI 患者的死亡率

A groundbreaking study published in a peer-reviewed medical journal has demonstrated the life-saving potential of a microaxial flow pump (Impella CP) in patients experiencing ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock. The study found that the use of the Impella CP, when combined with standard care, significantly reduced the risk of death compared to standard care alone.

同行评审医学杂志上发表的一项开创性研究表明，微轴流泵 (Impella CP) 对于患有 ST 段抬高型心肌梗死 (STEMI) 并发心源性休克的患者具有挽救生命的潜力。研究发现，与单独使用标准护理相比，使用 Impella CP 与标准护理相结合可显着降低死亡风险。

STEMI, a severe type of heart attack, occurs when a blood clot blocks a major coronary artery, cutting off blood flow to the heart muscle. Cardiogenic shock, a life-threatening complication of STEMI, develops when the heart is unable to pump enough blood to meet the body's needs.

STEMI 是一种严重的心脏病发作，当血凝块阻塞主要冠状动脉、切断流向心肌的血流时，就会发生 STEMI。心源性休克是 STEMI 的一种危及生命的并发症，当心脏无法泵出足够的血液来满足身体需要时，就会发生心源性休克。

The Impella CP is a small, percutaneous pump that is placed in the left ventricle of the heart. This pump assists in expelling oxygenated blood from the left ventricle to the body, thereby supporting circulation and reducing the workload on the failing heart.

Impella CP 是一种小型经皮泵，放置在心脏的左心室中。该泵有助于将含氧血液从左心室排出到身体，从而支持循环并减少衰竭心脏的工作负荷。

The study, conducted at multiple centers across the United States, enrolled 190 patients with STEMI and cardiogenic shock. Patients were randomized to receive either standard care alone or standard care plus the Impella CP.

该研究在美国多个中心进行，招募了 190 名 STEMI 和心源性休克患者。患者被随机分配接受单独标准护理或标准护理加 Impella CP 治疗。

The primary endpoint of the study was all-cause mortality at 180 days. The results showed that the use of the Impella CP, in addition to standard care, was associated with a lower risk of death compared to standard care alone (19.2% vs. 33.5%, p < 0.05).

该研究的主要终点是 180 天的全因死亡率。结果表明，与单独使用标准护理相比，在标准护理的基础上使用 Impella CP 可以降低死亡风险（19.2% vs. 33.5%，p < 0.05）。

While the use of the Impella CP was associated with a higher incidence of complications, such as bleeding and vascular injury, these complications were deemed manageable and outweighed by the survival benefits.

虽然使用 Impella CP 会导致较高的并发症发生率，例如出血和血管损伤，但这些并发症被认为是可以控制的，并且生存获益超过了这些并发症。

The findings suggest that the Impella CP can improve outcomes in patients with STEMI and cardiogenic shock. The study provides evidence that the use of mechanical circulatory support devices, such as the Impella CP, may play a crucial role in reducing mortality in this high-risk patient population.

研究结果表明，Impella CP 可以改善 STEMI 和心源性休克患者的预后。该研究提供的证据表明，使用机械循环支持装置（例如 Impella CP）可能在降低高危患者群体的死亡率方面发挥至关重要的作用。

Further research is needed to investigate the long-term effects of the Impella CP and to determine the optimal timing and duration of support in different patient subsets. However, the current study provides an important advance in the management of STEMI patients with cardiogenic shock, offering hope for improved survival rates.

需要进一步研究来调查 Impella CP 的长期影响，并确定不同患者亚群的最佳支持时机和持续时间。然而，目前的研究在心源性休克 STEMI 患者的治疗方面取得了重要进展，为提高生存率带来了希望。